Blue Earth, MN (PRWEB) July 29, 2013
Express Diagnostics Int’l, Inc. (EDI), manufacturer of DrugCheck® onsite drugs of abuse tests, looks forward to exhibiting at the American Association for Clinical Chemistry (AACC) Clinical Lab Expo July 30 through August 1 in Houston, Texas. In addition to the launch of a number of new products, EDI’s vice president of research and development will be presenting an abstract on the company’s new onsite test for hematocrit.
Products being introduced include an expanded catalog of 39 urine drug tests and detection levels – or cutoffs – for the international market, the DrugCheck semi-quantitative test for gamma-hydroxybutyric acid (GHB) in lateral-flow format, an innovative urine collection aid, two over-the-counter cleared disposable tests: the AlcoCheck® Breath Alcohol Screen and the Urinary Tract Infection test strip, and a new onsite test reader system in development.
The company’s expanded presence at the Clinical Lab Expo will include an abstract presentation by Steve Tyrrell, vice president of R&D at Express Diagnostics. Tyrrell will present “Preclinical development of a disposable, instrument-free device for measuring hematocrit” at 11:20 a.m., Tuesday, July 30, as part of the AACC OEM Lecture Series. The AnemiaCheck™ POC Quantitative Hematocrit Test is an entirely self-contained, disposable device designed to measure hematocrit levels with no instrumentation. The device is not currently available in the U.S. and will be available for export in the fourth quarter of 2013.
“We are very excited about the breadth and number of new products Express Diagnostics is introducing this year at AACC and we’re proud of our R&D team for the development of a revolutionary reader system for onsite testing devices that we’ll be demonstrating at our booth,” says Paul Johnson, CEO. “These product advancements, coupled with our significant growth over the past year, warranted our largest presence ever at the Clinical Lab Expo with a 10 foot by 20 foot exhibit space.”
The new urine drug tests and cutoffs offered under EDI’s DrugCheck brand bring the total number of tests available for export to 39. The new test strips will be of particular interest to international customers where several of the focus drugs have become much more prevalent in recent years. In addition to previously available tests, DrugCheck onsite cups and dip tests can now screen for clonazepam, EDDP, fentanyl, GHB, methadone (200 ng/mL), tramadol, and 16 different synthetic marijuana/cannabis (K2) compounds.
DrugCheck urine cups and dip tests are FDA 510(k) cleared for 17 drugs of abuse. The additional 22 drugs and cutoffs included in the expanded catalog of custom drug tests and cutoffs are available for export or forensic use only.
Visitors to the 2013 AACC Clinical Lab Expo can find Express Diagnostics Int’l at booth 1835/1837.
About Express Diagnostics Int’l, Inc.
Express Diagnostics Int’l manufactures and distributes DrugCheck® on-site urine and saliva screening devices for the detection of drugs of abuse, as well as a growing catalog of health screening devices. With accuracy comparable to laboratory testing, Express Diagnostics onsite devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab services. Learn more at drugcheck.com.
Read the full story at http://www.prweb.com/releases/2013/7/prweb10962914.htm.
Copyright©2012 Vocus, Inc.
All rights reserved